Tempus AI has acquired digital pathology firm Paige in an $81.3 million stock-based deal, enhancing its capabilities in cancer diagnostics and precision medicine. Paige's extensive dataset of nearly seven million digitized pathology slides, combined with its FDA-cleared AI applications, will bolster Tempus’ efforts in early cancer detection and accelerate biomarker discovery pipelines. The acquisition supports Tempus' vision to deliver comprehensive diagnostic insights earlier in patient care.